Arcus Biosciences Valuation Multiples

Arcus Biosciences Overview

About Arcus Biosciences

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Founded

2015

HQ

Employees

601

Website

arcusbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $213M

EBITDA: ($364M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Arcus Biosciences Financials

Arcus Biosciences reported last 12-month revenue of $213M and negative EBITDA of ($364M).

In the same LTM period, Arcus Biosciences generated $213M in gross profit, ($364M) in EBITDA losses, and had net loss of ($378M).

Arcus Biosciences P&L

In the most recent fiscal year, Arcus Biosciences reported revenue of $247M and EBITDA of ($335M).

Arcus Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Arcus Biosciences Stock Performance

Arcus Biosciences has current market cap of $3B, and enterprise value of $2B.

Arcus Biosciences' stock price is $20.37.

Arcus Biosciences Valuation Multiples

Arcus Biosciences trades at 8.4x EV/Revenue multiple, and (4.9x) EV/EBITDA.

Arcus Biosciences Financial Valuation Multiples

As of March 19, 2026, Arcus Biosciences has market cap of $3B and EV of $2B.

Equity research analysts estimate Arcus Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Arcus Biosciences has a P/E ratio of (6.7x).

Arcus Biosciences Margins & Growth Rates

Arcus Biosciences' revenue in the last 12 month declined by (55%).

Arcus Biosciences' revenue per employee in the last FY averaged $0.4M.

Arcus Biosciences' rule of 40 is (225%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Arcus Biosciences' rule of X is (307%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Arcus Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Arcus Biosciences M&A Activity

Arcus Biosciences acquired XXX companies to date.

Last acquisition by Arcus Biosciences was on XXXXXXXX, XXXXX. Arcus Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Arcus Biosciences Investment Activity

Arcus Biosciences invested in XXX companies to date.

Arcus Biosciences made its latest investment on XXXXXXXX, XXXXX. Arcus Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).